Lee Seungyeon, Lee Jae Kwang, Kim Seo Hee, Chung Eun Jee
Department of Ophthalmology, National Health Insurance Service Ilsan Hospital, Goyang, Republic of Korea,
Department of Ophthalmology, Yonsei University College of Medicine, Seoul, Republic of Korea,
Ophthalmologica. 2024;247(5-6):331-340. doi: 10.1159/000541055. Epub 2024 Sep 4.
In this study, we aimed to analyze the incidence of acute endophthalmitis after secondary intraocular lens (IOL) implantation in South Korea.
This study used information from the National Health Insurance Service (NHIS)-National Health Information Database (NHID). We identified patients who underwent secondary IOL implantation or IOL exchange surgeries during 2002-2021 due to diagnoses of IOL dislocation or mechanical complication of IOL. Postoperative endophthalmitis (POE) was defined as patients having received intravitreal antibiotic injection or vitrectomy for acute endophthalmitis diagnosed within 42 days after the claim for secondary IOL surgeries. All statistical analyses were performed with a significance level p < 0.05, and we used the univariate and multivariate Cox proportional hazard model to identify risk factors.
From 2002 to 2021, 39,364 patients received secondary IOL implantation, and acute POE was diagnosed in 62 patients. The overall incidence of acute POE was 0.16% during the 20-year period. More than half of the patients were diagnosed with POE within the first week after surgery. In the univariate analysis, there was a higher incidence of endophthalmitis in the group with pre-existing glaucoma (hazard ratio [HR], 1.945; 95% confidence interval [CI], 1.036-3.652; p = 0.0385) and the group undergoing concurrent vitrectomy (hazard ratio [HR], 2.329; 95% confidence interval [CI], 1.003-5.405; p = 0.0491).
The incidence of acute endophthalmitis after secondary IOL implantation in South Korea was similar to that of other countries. This is the largest retrospective claims data-based study of acute endophthalmitis after secondary IOL implantation in patients in South Korea.
在本研究中，我们旨在分析韩国二期人工晶状体（IOL）植入术后急性眼内炎的发生率。
本研究使用了来自韩国国民健康保险服务（NHIS）-国家健康信息数据库（NHID）的信息。我们确定了在2002年至2021年期间因人工晶状体脱位或人工晶状体机械并发症诊断而接受二期人工晶状体植入或人工晶状体置换手术的患者。术后眼内炎（POE）定义为在二期人工晶状体手术索赔后42天内被诊断为急性眼内炎并接受玻璃体内抗生素注射或玻璃体切除术的患者。所有统计分析的显著性水平为p < 0.05，我们使用单因素和多因素Cox比例风险模型来识别风险因素。
2002年至2021年期间，39364例患者接受了二期人工晶状体植入，62例患者被诊断为急性POE。20年期间急性POE的总体发生率为0.16%。超过一半的患者在术后第一周内被诊断为POE。在单因素分析中，既往有青光眼的组（风险比[HR]，1.945；95%置信区间[CI]，1.036 - 3.652；p = 0.0385）和同时进行玻璃体切除术的组（风险比[HR]，2.329；95%置信区间[CI]，1.003 - 5.405；p = 0.0491）眼内炎的发生率较高。
韩国二期人工晶状体植入术后急性眼内炎的发生率与其他国家相似。这是韩国基于回顾性索赔数据对二期人工晶状体植入术后急性眼内炎进行的最大规模研究。
